Crinetics Pharmaceuticals


Biopharmaceutical company focused on discovery, development, and commercialization of small-molecule therapies for endocrine and endocrine-related diseases. Internal R&D emphasizes GPCR-targeted, non-peptide small molecules and targeted delivery approaches; clinical development spans Phase 1–3 programs and regulatory submissions in multiple regions. The company integrates patient insights into trial design and operates commercialization activities in the U.S. and Europe.

Industries

Biotechnology
Health Care
Pharmaceutical
Therapeutics
Biotech & Pharmaceuticals
Pharmaceutical and biotechnology
Pharmaceutical Manufacturing

Nr. of Employees

large (251-1000)

Crinetics Pharmaceuticals


Patents

Crystalline forms of somatostatin modulators

US-12617767-B2

View Details

Nonpeptide somatostatin type 5 receptor agonists and uses thereof

US-12600709-B2

View Details

Gem-disubstituted piperidine melanocortin subtype-2 receptor (MC2R) antagonists and uses thereof

US-12492181-B2

View Details

Melanocortin subtype-2 receptor (MC2R) antagonists and uses thereof

US-12479825-B2

View Details

Melanocortin subtype-2 receptor (MC2R) antagonists and uses thereof

US-12479828-B2

View Details

Spirocyclic piperidine melanocortin subtype-2 receptor (MC2R) antagonists and uses thereof

US-12466829-B2

View Details
View All Patents

Products

Oral SST2 receptor agonist for acromegaly and NET-related carcinoid syndrome (paltusotine)

A once-daily, orally administered, non-peptide, selective somatostatin receptor subtype 2 agonist developed for treatment of acromegaly and investigated for carcinoid syndrome in neuroendocrine tumors.

Oral MC2R (ACTH receptor) antagonist for ACTH-driven adrenal disease (atumelnant)

An investigational once-daily, oral melanocortin type 2 receptor antagonist designed to block ACTH activity at the adrenal cortex; developed for congenital adrenal hyperplasia and ACTH‑dependent Cushing’s syndrome.

Non-peptide drug conjugate targeting SST2-expressing tumors (CRN09682)

A targeted small-molecule drug conjugate designed to selectively deliver a cytotoxic payload to SST2-expressing neuroendocrine and other solid tumors; progressed toward a Phase 1 clinical study.


Services

Programs to support patient education, testing access, and post-approval support across endocrine indications (example: patient outreach and testing pathways).

Business development and licensing of programs and technologies both inbound and outbound to accelerate development and commercialization.

Expertise Areas

  • Endocrinology-focused drug discovery
  • GPCR-targeted therapeutics
  • Small-molecule oral therapeutic development
  • Targeted payload delivery for oncology
  • Show More (6)

Key Technologies

  • Small-molecule GPCR modulators
  • Oral receptor agonist/antagonist chemistry
  • Non-peptide drug conjugates (targeted payload delivery)
  • Clinical pharmacology and PK/ADME assessment
  • Show More (3)

News & Updates

Perspective on the EC approval of the first once-daily oral therapy for acromegaly in the EU and the company’s European commercialization plans.

An orally administered selective SST2 agonist was approved for treating adults with acromegaly who had inadequate response to surgery or are not surgical candidates.


Similar organizations

Browse all ORGANIZATIONS

JOIN OUR MAILING LIST

Stay Connected with MTEC

Keep up with active and upcoming solicitations, MTEC news and other valuable information.